Flatiron Health

Flatiron Health is presenting seven abstracts at this year’s #ASH24 that leverage our #realworlddata at scale to improve our understanding of current therapies and identify treatment gaps for patients with #hematologicmalignancies. Check out what Flatiron experts will be onsite and schedule time with them to learn more: https://spkl.io/6045fnHpP

Join a panel of experts from Exact Sciences, Bristol Myers Squibb, and Exigent Research Network, moderated by Flatiron Health to gain insight into perspectives and experiences with pragmatic clinical trial design. ??? Moderated by Ivy Altomare MD, Flatiron Health ?? Wednesday, December 4th from 12-1 PM ET Secure your spot & ask our panel of experts your questions directly. Register now: https://spkl.io/6043fn1Sc

ANNOUNCED TODAY: Flatiron Health and Willowglade Technologies to partner to bring Willowglade’s Unified Digital Patient Experience? Platform to practices using Flatiron’s OncoEMR? through Flatiron’s Trusted Partner Network. Willowglade’s platform, together with OncoEMR, positions practices to spend more time with patients and provide a better care experience for clinicians and their patients. Learn more: https://spkl.io/6045fVfuh

Flatiron Health is presenting five abstracts at this year’s #ISPOREurope that leverage our high-quality, multinational oncology data assets and novel methodological approaches, unlocking critical evidence to accelerate access to cancer treatments worldwide. Check out what Flatiron experts will be onsite and schedule time with them to learn more: https://lnkd.in/eSXMzi8X

ANNOUNCED TODAY: Flatiron Health to present seven abstracts at #ASH24. Through our research accepted at this year’s conference, Flatiron’s scientists and collaborators are using our #RWD at scale to improve our understanding of current therapies & identify treatment gaps for patients with hematologic malignancies. Learn more: https://spkl.io/6044fpLfI

With 230,000 new cases of lung cancer a year in the United States, it remains one of the most active areas of #cancerresearch today. This #LungCancerAwarenessMonth, we’re highlighting one of Flatiron Health’s #1000Publications which used #RWD to define timelines for progression-free NSCLC patients to discontinue immunotherapy treatments after two years without compromising survival benefits. Using #RWD, this research has the potential for direct impact on the quality of life for patients with NSCLC. If you’re interested in reading the full study, click here: https://spkl.io/6045fplaP

Flatiron’s Neal Meropol spoke on an insightful panel at the Friends of Cancer Research Annual Meeting earlier today building off a recently published white paper. The conversation revealed a few key insights, including: ?? Incorporating pragmatic elements into #clinicaltrial designs can enhance generalizability and efficiency ?? Opportunities for pragmatic trial elements exist broadly, however, identifying appropriate pragmatic elements based on the research question, trial objectives, and clinical setting is critical ?? Tech like #AI-enabled trial matching, EHR-to-EDC connectors, and more are viable pragmatic elements that can lower the burden and reduce the complexity of clinical trials Read the full white paper to learn more: https://spkl.io/6046fpWaA

ANNOUNCED TODAY: Flatiron Health is integrating Tempus AI’s comprehensive genomic testing into OncoEMR?, providing for the 4,200+ providers across the Flatiron network with access to Tempus’ suite of testing options and enhancing their ability to deliver personalized cancer care. Learn more about how this initiative will expand possibilities at the point of care: https://spkl.io/6049fpjy1

We're driven by a purpose: to improve and extend lives by learning from every person with cancer. Our Life Sciences Hub in #RaleighDurham is growing, and we're looking for problem solvers with integrity at their core. Make a difference in cancer care—apply today: https://shorturl.at/LeL8B

Flatiron FORUM, a consortium of multiple biopharma and life science companies that work closely with Flatiron, have recently demonstrated opportunities to close evidence gaps and address transportability research needs globally on a series of pre-competitive studies. Read a recent blog by Flatiron’s Blythe Adamson, PhD, MPH for more on the potential of Flatiron’s EHR-derived data from the UK, Germany, and Japan, on-going projects, and future directions to expand multi-national data capabilities and refine our methodologies that will play a pivotal role in shaping the future of oncology and global health policy. Heading to #ISPOREurope? Reach out to our team of experts today to connect on this and more onsite: https://lnkd.in/eSXMzi8X